NCT02184611 - A 24 Week Efficacy Study of Inhaled Umeclidinium (UMEC) in Patients of Chronic Obstructive Pulmonary Disease (COPD) Using a Novel Dry Powder Inhaler (NDPI) | Biotech Hunter

Enrollment

308

Participants

Timeline

Start Date

May 9, 2016

Primary Completion Date

November 8, 2017

Study Completion Date

November 8, 2017

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Umeclidinium bromide

Blended with lactose and magnesium stearate dry white powder of umeclidinium 62.5 mcg to be inhaled via a NDPI

DRUG

Placebo

Blended with lactose and magnesium stearate dry white powder to be inhaled via a NDPI

Trial Locations (26)

100034

GSK Investigational Site, Beijing

110004

GSK Investigational Site, Shenyang

110015

GSK Investigational Site, Shenyang

130041

GSK Investigational Site, Changchun

200433

GSK Investigational Site, Shanghai

214023

GSK Investigational Site, Wuxi

250013

GSK Investigational Site, Jinan

266071

GSK Investigational Site, Qingdao

330006

GSK Investigational Site, Nanchang

400038

GSK Investigational Site, Chongqing

410013

GSK Investigational Site, Changsha

510120

GSK Investigational Site, Guangzhou

510630

GSK Investigational Site, Guangzhou

524001

GSK Investigational Site, Zhanjiang

570311

GSK Investigational Site, Haikou

750004

GSK Investigational Site, Yinchuan

010017

GSK Investigational Site, Hohhot

Unknown

GSK Investigational Site, Taiyuan

GSK Investigational Site, Hangzhou

GSK Investigational Site, Chongqing

410-719

GSK Investigational Site, Gyeonggi-do

130-709

GSK Investigational Site, Seoul

130-872

GSK Investigational Site, Seoul

380-704

GSK Investigational Site, Seoul

442-723

GSK Investigational Site, Suwon